secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2022-10-12T23:59:59+00:00
Accession:  0001819790-22-000033
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus expands board to nine, appoints Scott Morrison, plans Chairperson transition
--------------------------------------------------------------------------------

- Scott Morrison appointed to Board as Class III director effective Oct 6, 2022, and as Audit Committee Chair.
- Board expanded from eight to nine directors; new Commercial Committee formed with Morrison, Yarno, Yeu-Lin, Crane (Chair).
- Michael Ackermann expected to transition off Board by end of 2022; Bobak Azamian to become Chairperson, Wendy Yarno Lead Independent Director.
- Morrison receives initial equity grant: option for 14,000 shares plus 4,000 RSUs.
- Morrison is independent under Nasdaq standards and qualifies as audit committee financial expert.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/tars-20221006.htm
  HTML page:      https://secwatch.observer/filing/0001819790-22-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer